RxDoctor Payments Data

Mikhail Meyerovich, MD

Psychiatry · Santa Barbara, CANPI 1073506952

Payments from drug & device makers

$2,155in general payments, 2019–2025

Across 133 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$652
  • Takeda Pharmaceuticals U.S.A., Inc.$423
  • Sunovion Pharmaceuticals Inc.$236
  • Neurocrine Biosciences, Inc.$168
  • Vanda Pharmaceuticals Inc.$119
  • Ironshore Pharmaceuticals Inc.$110
  • plus $447 from 9 others

What the payments were for

  • Food & beverage$2,155100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,155 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$10,393
Medicare patients
31
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl14$20,908
FanaptIloperidone11$12,516
TrintellixVortioxetine Hydrobromide15$9,860
LexaproEscitalopram Oxalate14$5,973
VyvanseLisdexamfetamine Dimesylate14$5,473
Bupropion XlBupropion Hcl96$2,879
Methylphenidate ErMethylphenidate Hcl17$2,185
Aripiprazole57$2,065
Oxcarbazepine27$2,055
Duloxetine Hcl51$1,810
Ziprasidone Hcl28$1,708
Clomipramine Hcl12$1,622
Zolpidem Tartrate ErZolpidem Tartrate23$1,394
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine43$1,231
Gabapentin65$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Lexapro$652$26,88128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$423$15,33229 claims
Vanda Pharmaceuticals Inc.Fanapt$119$12,51611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →